Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical Holdings Group has disclosed that the trustee of its 2022 share award scheme purchased 9 million shares on the market on 18 December 2025, representing about 0.0983% of its issued share capital, at an average price of roughly HK$1.2271 per share. The board views this share purchase as a move to strengthen its equity base and incentivise its team, supporting the company’s current growth phase and long-term strategy. Management highlighted strong progress in 2025 under its dual-drive strategy of innovative drugs and global medical aesthetics expansion, including full-value-chain breakthroughs at core subsidiaries Xuanzhu Biopharm and Huisheng Biopharm—from R&D and launches to inclusion in China’s National Reimbursement Drug List—alongside rapid commercialization of self-developed regenerative medical aesthetics products and entry into the European market via its investment in Swiss firm Suisselle, developments that the company believes will enhance competitiveness, open new growth avenues, and bolster shareholder value over time.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is an innovation-driven international pharmaceutical and medical aesthetics company listed on the Hong Kong Stock Exchange since 2010. It operates a comprehensive biopharmaceutical platform covering independent R&D, a broad global product pipeline, robust registration capabilities, efficient multi-dosage manufacturing, and a mature sales network, with a strategic focus on a dual-engine model combining medical aesthetics and biopharmaceutical businesses to build a leading position in China’s market.
Average Trading Volume: 38,360,370
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.76B
See more data about 0460 stock on TipRanks’ Stock Analysis page.